Abstract:Invasive fungal infections caused by drug-resistant organisms are an emerging threat to heavily immunosuppressed patients with hematological malignancies. Modern early antifungal treatment strategies, such as prophylaxis and empirical and preemptive therapy, result in long-term exposure to antifungal agents, which is a major driving force for the development of resistance. The extended use of central venous catheters, the nonlinear pharmacokinetics of certain antifungal agents, neutropenia, other forms of intense immunosuppression, and drug toxicities are other contributing factors. The widespread use of agricultural and industrial fungicides with similar chemical structures and mechanisms of action has resulted in the development of environmental reservoirs for some drug-resistant fungi, especially azole-resistant Aspergillus species, which have been reported from four continents. The majority of resistant strains have the mutation TR34/L98H, a finding suggesting that the source of resistance is the environment. The global emergence of new fungal pathogens with inherent resistance, such as Candida auris, is a new public health threat. The most common mechanism of antifungal drug resistance is the induction of efflux pumps, which decrease intracellular drug concentrations. Overexpression, depletion, and alteration of the drug target are other mechanisms of resistance. Mutations in the ERG11 gene alter the protein structure of C-demethylase, reducing the efficacy of antifungal triazoles. Candida species become echinocandin-resistant by mutations in FKS genes. A shift in the epidemiology of Candida towards resistant non-albicans Candida spp. has emerged among patients with hematological malignancies. There is no definite association between antifungal resistance, as defined by elevated minimum inhibitory concentrations, and clinical outcomes in this population. Detection of genes or mutations conferring resistance with the use of molecular methods may offer better predictive values in certain cases. Treatment options for resistant fungal infections are limited and new drugs with novel mechanisms of actions are needed. Prevention of resistance through antifungal stewardship programs is of paramount importance.

Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies

Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species

The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens

ANTIFUNGAL RESISTANCE: A GROWING CONCERN

Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: analysis of trends and outcomes

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

Pathogenicity and drug resistance in Candida albicans and other yeast species. A review

Threats from the Candida parapsilosis complex: the surge of multidrug resistance and a hotbed for new emerging pathogens

Antifungal Drug Resistance: An Emergent Health Threat

Antifungal resistance: an emerging reality and a global challenge

Candida auris: Epidemiology and Antifungal Strategy

The Candida auris Alert: Facts and Perspectives

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

Combatting the evolution of antifungal resistance in Cryptococcus neoformans

Investigational Agents for the Treatment of Resistant Yeasts and Molds

The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida

Overview on the Infections Related to Rare Candida species

Review on Current Status of Echinocandins Use

Antifungal drug resistance in Candida: a special emphasis on amphotericin B

Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal